[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343864-105":59,"doc-detail-343864-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","hypoxia-is-linked-to-acquired-resistance-to-immune-checkpoint-inhibitors-in-lung-cancer","Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer","","Immune checkpoint inhibitors (ICIs) benefit only a subset of non-small cell lung cancer patients, and roughly half of responders later develop acquired resistance (AR). Using murine Msh2 knockout lung tumors, researchers modeled initial response followed by AR to anti-PD-1 ± anti-CTLA-4. Resistant tumors showed fewer infiltrating T cells and lowered cancer-cell intrinsic MHC-I and MHC-II, while retaining responsiveness to IFNγ. Extensive hypoxic regions emerged, and a hypoxia single-cell transcriptional signature correlated with worse progression-free survival in NSCLC patients receiving anti-PD-1/PD-L1 therapy. Hypoxia-activated pro-drug treatment delayed AR to ICIs in mice.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hypoxia-is-linked-to-acquired-resistance-to-immune-checkpoint-inhibitors-in-lung-cancer/343864/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hypoxia-is-linked-to-acquired-resistance-to-immune-checkpoint-inhibitors-in-lung-cancer/343864.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is acquired resistance a major concern for ICIs in NSCLC?","Question",{"text":112,"@type":113},"Only a subset of NSCLC patients achieve durable benefit from ICIs, and about half of initial responders eventually develop acquired resistance, making it an ongoing clinical challenge.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What immune and antigen-presentation changes were observed in resistant tumors?",{"text":117,"@type":113},"Resistant tumors had decreased infiltrating T cells and reduced intrinsic MHC-I and MHC-II levels in cancer cells, although they still responded to IFNγ.",{"name":119,"@type":110,"acceptedAnswer":120},"How did hypoxia influence resistance and patient outcomes?",{"text":121,"@type":113},"Resistant tumors contained extensive hypoxic regions, and a hypoxia signature from single-cell profiling was associated with decreased progression-free survival in NSCLC patients treated with anti-PD-1/PDL1 therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343864,1790585428,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","ARTICLE  \nHypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer  \nCamila Robles-Oteza1􀀁, Katherine Hastings2􀀁, Jungmin Choi3,4􀀁, Isabelle Sirois5􀀁, Arvind Ravi6,7􀀁, Francisco Expósito2􀀁, Fernando de Miguel2􀀁, James R. Knight8􀀁, Francesc López-Girldez8􀀁, Hyejin Choi9􀀁, Nicholas D. Socci10􀀁, Taha Merghoub9,11,12􀀁, Mark Awad13,14􀀁, Gad Getz6,15,16􀀁, Justin Gainor17􀀁, Matthew D. Hellmann18􀀁, ´Etienne Caron5,19􀀁, Susan M. Kaech20􀀁, and Katerina Politi2,21􀀁  \nDespite the established use of immune checkpoint inhibitors (ICIs) to treat non-small cell lung cancer (NSCLC), only a subset of patients benefit from treatment and ∼50% of patients whose tumors respond eventually develop acquired resistance (AR). To identify novel drivers of AR, we generated murine Msh2 knock-out (KO) lung tumors that initially responded but eventually developed AR to anti-PD-1, alone or in combination with anti-CTLA-4. Resistant tumors harbored decreased infiltrating T cells and reduced cancer cell-intrinsic MHC-I and MHC-II levels, yet remained responsive to IFNγ. Resistant tumors contained extensive regions of hypoxia, and a hypoxia signature derived from single-cell transcriptional profiling of resistant cancer cells was associated with decreased progression-free survival in a cohort of NSCLC patients treated with anti-PD-1/PDL1 therapy. Targeting hypoxic tumor regions using a hypoxia-activated pro-drug delayed AR to ICIs in murine Msh2 KO tumors. Thus, this work provides a rationale for targeting tumor metabolic features, such as hypoxia, in combination with immune checkpoint inhibition.  \nIntroduction  \nImmune checkpoint inhibitors (ICIs) have become a first-line standard of care, in combination with chemotherapy, for many patients with advanced non-small cell lung cancer (NSCLC) (Borghaei et al., 2015; Brahmer et al., 2015; Recket al., 2016; Planchard et al., 2018) . However, only a subset of patients receive durable clinical benefit from these agents, and ∼50–60% of patients whose tumors initially respond eventually develop acquired resistance (AR) (Gettinger et al., 2018; Schoenfeld and Hellmann, 2020; Memon et al., 2024; Ricciuti et al., 2024) . As increasing numbers of patients receive immune checkpoint inhibitor therapy, particularly in the first-line setting and during earlier stages of the disease, AR will continue to grow as a clinical challenge (Gettinger et al., 2018; Herbst et al., 2020) . Thus, understanding the  \nunderlying mechanisms that allow tumors to escape during therapy is essential to inform strategies that can delay or overcome resistance.  \nClinical studies of resistance to immune checkpoint inhibition have converged on the antigen presentation and interferon (IFN) signaling pathways as important mediators of resistance (Gettinger et al., 2017; Sade-Feldman et al., 2018; Zaretsky et al., 2016; Le et al., 2017; Sucker et al., 2017). Alterations in β-2 microglobulin (B2M), a component of the major histocompatibility complex (MHC) class I complex that is critical for its stable expression at the cell surface, have been identified in lung cancer, colorectal cancer, and melanoma with resistance to ICIs (Gettinger et al., 2017; Sade-Feldman et al., 2018; Zaretsky et al., 2016; Le et al., 2017) . Loss-of-function mutations in JAK1/2 were  \n............................................................................................................................... ..............................................  \n1Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA; 2Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA; 3Department of Genetics, Yale School of Medicine, New Haven, CT, USA; 4Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea; 5CHU Sainte-Justine Research Center, Montreal, Canada; 6Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA; 7Lank Center for Genitourinary Oncology, Dana-Farber Ca","cbCaijLDHfvKeJdw","https://ap.wps.com/l/cbCaijLDHfvKeJdw","pdf",7824442,28,"English","# Introduction\n## Background on ICIs and acquired resistance\n## Mechanisms: antigen presentation and interferon signaling\n## Hypoxia as a driver and therapeutic target","[{\"question\":\"Why is acquired resistance a major concern for ICIs in NSCLC?\",\"answer\":\"Only a subset of NSCLC patients achieve durable benefit from ICIs, and about half of initial responders eventually develop acquired resistance, making it an ongoing clinical challenge.\"},{\"question\":\"What immune and antigen-presentation changes were observed in resistant tumors?\",\"answer\":\"Resistant tumors had decreased infiltrating T cells and reduced intrinsic MHC-I and MHC-II levels in cancer cells, although they still responded to IFNγ.\"},{\"question\":\"How did hypoxia influence resistance and patient outcomes?\",\"answer\":\"Resistant tumors contained extensive hypoxic regions, and a hypoxia signature from single-cell profiling was associated with decreased progression-free survival in NSCLC patients treated with anti-PD-1/PDL1 therapy.\"}]","Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer | PDF",1790052334,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/426d38425141fb2d79e0eddfd4163beb.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58da99b8bd8a2504138d99c5ef462571.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5120356cd9c4a277d54668c9035ebf87.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4554423a430f5ebdfc1c4abe1f09833f.webp",980,1268]